Lyv

What Lyv does

Lyv Healthcare SAS is a French digital health company headquartered in Nantes that develops Lyv Endo®, a Class I Digital Medical Device (CE-marked under EU Regulation 2017/745) delivered as a mobile application for self-management of endometriosis. The product is structured as a six-month program built on five multidisciplinary pillars (knowledge, mental wellbeing, physical activity, nutrition, and sexual health), with nearly 250 co-developed educational resources and monthly tracking of symptoms and EHP5 quality-of-life scores. Content is validated by a scientific committee of 15+ French endometriosis specialists, and the company is running three clinical studies — the REALYV-1 observational study, a randomized controlled trial, and a retrospective study — to generate real-world evidence and support French social security (Assurance Maladie) reimbursement.

The commercial model is a freemium-to-paid hybrid: Lyv Endo® Suivi (symptom tracking) is free on iOS and Android, while the full Lyv Endo® Thérapie Numérique is accessed at no direct cost to patients either through medical prescription from specialist prescribers or via B2B partnerships with French employers and complementary health insurers (mutuelles, including MGEN and Mutuelles Impact). The company serves three customer segments: women with diagnosed endometriosis as end users, specialist healthcare professionals as prescribers, and employers/mutuelles as B2B payers. Lyv reports that more than 10,000 patients have been supported, with 97.9% showing significant quality-of-life or symptom improvement after three months of use and an average 11-point EHP5 improvement.

Lyv is privately held and pre-commercial at scale, having closed a ~€2.5M (~$2.7M) round in February 2025 led by Mutuelles Impact with participation from Abeille Impact Investing France, INCO Investissement, Impactivist, MGEN and XAnge. The company has 11–50 employees and a single Nantes office. It is also publicly supported through French innovation programs (Bpifrance/France 2030, Nantes Métropole, Investir L'Avenir, Paris Santé Campus) and is a member of France Biotech. A separate Dutch battery/energy startup sharing the Lyv name was acquired by Van Dorp in 2025 and is unrelated to this French digital therapeutic business.

Name

Lyv

Legal name

LYV HEALTHCARE

Website

https://lyv.app

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Lyv Healthcare is a Nantes-based French digital health company that markets Lyv Endo®, a CE-marked Class I Digital Medical Device mobile app for endometriosis self-management, sold via freemium consumer download and B2B partnerships with French employers and mutuelles to women with endometriosis.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Women's Health

NAICS

Custom Computer Programming Services (541511), Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372), Services-Health Services (8000)

akta.pro primary industry

Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

akta.pro secondary industries

DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Digital therapeutic endometriosis
• Women's health app
• Chronic disease management
• Digital medical device
• Endometriosis self-care

Headquarters

HQ city

Nantes

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Freemium App Distribution: Lyv Endo® Suivi (the symptom tracking version) is available free of charge to all users. Lyv Endo® Thérapie Numérique (the full digital therapeutic) is accessible at no direct cost to patients via: (1) prescription by a healthcare professional, or (2) coverage through enterprise and health insurance partners. The company is pursuing social security reimbursement (prise en charge by Assurance Maladie).
2. B2B / Enterprise Partnerships: Lyv partners with employers and complementary health insurance providers (mutuelles) to subsidize employee/member access to the full Lyv Endo® therapy program. This B2B channel provides a revenue stream while reducing direct cost barriers for patients.
3. Prescription-Based Access: The full Lyv Endo® Thérapie Numérique is accessible via medical prescription, positioning the product within the healthcare reimbursement pathway. A controlled randomized clinical trial is ongoing specifically to support future social security (Assurance Maladie) reimbursement.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Lyv develops and commercializes Lyv Endo®, a CE-marked Class I Digital Medical Device (under EU Regulation 2017/745) delivered as a mobile application for the self-management of endometriosis. The product suite includes a free symptom-tracking module (Lyv Endo® Suivi) and a full 6-month personalized digital therapy program (Lyv Endo® Thérapie Numérique) structured around five multidisciplinary pillars: disease knowledge, mental wellbeing, physical activity, nutrition, and sexual/affective health. The platform is built on an ISO 13485-certified quality management system and is targeted at women diagnosed with endometriosis, distributed directly via app stores and through healthcare professional prescriptions or B2B partner coverage.

Product overview

Lyv (Lyv Healthcare) offers Lyv Endo®, a digital medical device (Class I) for endometriosis management. The product suite consists of Lyv Endo® Suivi (free symptom tracking module) and Lyv Endo® Thérapie Numérique (prescription-based full therapy program). The platform is accessible via iOS and Android mobile applications and provides a 3-month personalized program based on 5 pillars: disease knowledge, physical activity, nutrition, mental well-being, and sexual/affective life. The company is pursuing French national health insurance reimbursement.

Differentiator

Problem solved

Functional benefit

Brands

• Lyv Endo: Digital therapeutic program for endometriosis management based on a 5-pillar multidisciplinary approach, available as a Class I Digital Medical Device (DMN) with CE marking under EU Regulation 2017/745.
• Lyv Endo Suivi
• Lyv Endo Thérapie Numérique
• Lyv Research

Products and services

• Lyv Endo® Thérapie Numérique Full digital therapeutic application for endometriosis self-management. Provides a 6-month personalized program structured around five multidisciplinary pillars (Knowledge, Mental Wellbeing, Physical Activity, Nutrition, Sexual Health) with hundreds of tools, exercises, and tips adapted to user symptoms. Available via medical prescription or B2B partner coverage at no direct cost to patients. Designed for adult women diagnosed with endometriosis as a complement to medical care.
• Lyv Endo® Suivi Free symptom and quality-of-life tracking module within the Lyv Endo® app. Allows patients with endometriosis to log symptoms monthly and visualize symptom evolution and quality-of-life scores (including EHP5 endometriosis-specific scores). Serves as the freemium entry point to the full Lyv Endo® Thérapie Numérique program. Available on iOS and Android.

Quantifiable outcome

• 97.9% of Lyv Endo® users significantly improve their quality of life or symptoms after 3 months of use
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Paris Santé CampusminorOthersLyv Healthcare is associated with Paris Santé Campus (displayed on the website logo section), a healthcare innovation campus in Paris. The nature of the partnership is not specified.
• France BiotechminorOthersLyv Healthcare is listed as a member or partner of France Biotech (the French healthtech industry association), evidenced by logo presence on the website. France Biotech supports healthtech companies in regulatory, financial, and strategic matters.
• Employer and Complementary Health Insurance PartnerscoreGTM or Marketing PartnerLyv partners with French employers and complementary health insurers (mutuelles) to subsidize employee/member access to Lyv Endo® Thérèse Numérique. These B2B partnerships are a key distribution and revenue channel enabling patients to access the full therapy at no direct cost. The company references working daily with partners to support financial access.
• Healthcare Professionals and Research CenterscoreStrategic or Co-development PartnerLyv Healthcare collaborates with over 15 endometriosis specialist healthcare professionals (gynecologists, pain specialists, physiotherapists, nutritionists, sexologists, psychologists, radiologists) and research centers (including Inserm at Institut Cochin) to co-develop and validate Lyv Endo® content and advance endometriosis research. Some healthcare professionals hold minor equity stakes in Lyv Healthcare as disclosed on the transparency portal.
• CNIL (Commission Nationale de l'Informatique et des Libertés)minorOthersLyv's REALYV-1 observational study is conducted under CNIL methodology reference MR-004, demonstrating regulatory compliance with French data protection requirements for health research.
• Health Data HubminorOthersLyv's research projects are published on the Health Data Hub, a French government platform for health data research transparency and accessibility.
• Transparence.Santé.gouv.frminorOthersLyv Healthcare publishes all agreements, advantages, remuneration, and donations related to healthcare professionals on the public Transparence.Santé.gouv.fr database, as required by French healthcare transparency regulations. This ensures compliance with the French Public Health Code on conflicts of interest.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Maven Clinic: Maven Clinic is a large virtual women's and family health platform offering longitudinal care across fertility, pregnancy, postpartum, and chronic conditions. It is comparable to Lyv as a digitally delivered women's health program but operates at far broader scope and scale without the regulated DTx positioning.
• Tia: Tia is a women's health primary care platform combining in-person clinics with virtual care across gynecology, mental health, and primary care. It is comparable to Lyv in targeting women's chronic gynecological conditions but at a broader, hybrid in-person/virtual model.

Direct peers

• HelloBetter: HelloBetter (GET.ON) is a German digital therapeutics company with multiple reimbursed prescription DTx products (e.g., for depression, insomnia, burnout) approved under Germany's DiGA pathway. It is highly comparable to Lyv as a European prescription-grade digital therapeutic company pursuing reimbursement and HCP-led prescription channels.
• Kaia Health: Kaia Health is a digital therapeutics company focused on musculoskeletal pain and chronic conditions, delivering app-based self-management programs with clinical evidence. It is comparable to Lyv in DTx category, multidisciplinary pain self-management approach, and pursuit of reimbursement pathways.
• Mahana Therapeutics: Mahana Therapeutics develops FDA-cleared prescription digital therapeutics for chronic conditions such as IBS. It is comparable to Lyv as a regulated DTx company targeting a specific chronic condition with a prescription-based, evidence-driven business model.
• Sidekick Health: Sidekick Health is a European digital therapeutics platform delivering app-based lifestyle and condition management programs (e.g., cancer, IBD, cardiovascular) in partnership with payers and pharma. It is comparable to Lyv as a DTx operator with payer/B2B channels and chronic-condition self-management design.
• Oviva: Oviva is a European digitally enabled therapy provider for obesity, diabetes, and related metabolic conditions, reimbursed by statutory health insurers in several countries. It is comparable to Lyv as a European digital therapeutic reimbursed via national health systems, with payer-led distribution.

Emerging players

• Curable: Curable is a digital chronic pain program combining pain neuroscience education, CBT, and mindfulness. It is comparable to Lyv as a chronic pain self-management app using multidisciplinary non-pharmacological approaches, though without Lyv's regulatory DTx status.
• Endodiag: Endodiag is a French diagnostics company developing tools to improve early diagnosis of endometriosis. It is comparable to Lyv as a French endometriosis-focused company addressing the same patient pathway, but on the diagnostic side rather than self-management/therapeutic.

Regional players

• Doctolib: Doctolib is the dominant French healthcare appointment, teleconsultation, and software platform used by HCPs and patients across France. It is comparable to Lyv as a French digital health company whose distribution depends on HCP adoption, though Doctolib operates at vastly broader scale and infrastructure layer.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCTAVhORDQV7STi4xXc-3yzA
• Facebookfacebook.com/lyv.endo
• LinkedInlinkedin.com/company/lyv-app
• Instagraminstagram.com/lyv.endo

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyv